Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
March 14, 2023 07:05 ET
|
Virios Therapeutics
ATLANTA, March 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
January 05, 2023 07:00 ET
|
Virios Therapeutics
ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat...